Reversion analysis reveals the in vivo immunogenicity of a poorly MHC I-binding cancer neoepitope

Reversion analysis reveals the in vivo immunogenicity of a poorly MHC I-binding cancer neoepitope

The immunogenicity of peptides is believed to be determined by their high-affinity binding to MHC I. Here authors show that low-affinity MHC I-peptide interactions are also able to trigger robust T cell response and anti-tumour immunity in vivo.

Bibliographic Details
Main Authors: Hakimeh Ebrahimi-Nik, Marmar Moussa, Ryan P. Englander, Summit Singhaviranon, Justine Michaux, HuiSong Pak, Hiroko Miyadera, William L. Corwin, Grant L. J. Keller, Adam T. Hagymasi, Tatiana V. Shcheglova, George Coukos, Brian M. Baker, Ion I. Mandoiu, Michal Bassani-Sternberg, Pramod K. Srivastava
Format: Article
Language:English
Published: Nature Portfolio 2021-11-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-021-26646-5

Internet

https://doi.org/10.1038/s41467-021-26646-5

Similar Items